Abstract
In the late 1970s, there was confusion regarding the best management for osteosarcoma. The benefit of chemotherapy had not been established and which chemotherapy could be used was even more uncertain. The European Osteosarcoma Intergroup (EOI) was established in order to conduct randomised studies to determine the best treatment for this tumour. Their first study 80831 established that a two drug combination of CDDP/DOX was safe and improved the survival rate over previous regimes with suboptimal chemotherapy. The CDDP/DOX was superior to a less intense CDDP/DOX/MTX regime. The second study 80861 compared the CDDP/DOX arm with a multi-drug Rosen-T10 regime. In almost 400 patients, there was the difference in outcome between the two arms. However, adherence to the protocol and completion of allocated treatment was substantially less good in the prolonged 42 week multi-drug regime compared to the two drug arm. The third study 80961 investigated interval compression i.e. if the CDDP/DOX when given every 2 weeks with GCSF superior to the same two drugs given every 3 weeks. There was no difference in survival between the arms, although there was a better histologic response rate in the compressed arm. Three randomised controlled trials on this rare disease have taken more than 20 years to accrue a sufficient sample of patients. The overall outcome has changed little in this time. Large multinational studies are needed to be able to answer these important questions in a timely fashion
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Edmondson JH, Green SJ, Ivins JC, et al. A controlled pilot study of high-dose methotrexate: a postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol.. 1984;2:156.
Jaffe N, Frie E III, Watts H, Raggis D. High-dose methotrexate in osteogenic sarcoma: a 5-year experience. Cancer Treat Rep.. 1978;6:259-264.
Rosen G, Nirenberg A. Chemotherapy for osteogenic sarcoma: an investigative method, not a recipe. Cancer Treat Rep.. 1982;66:1687-1697.
Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma. Cancer.. 1982;49:1221-1230.
Friedmann MA, Carter S. The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol.. 1972;4:482-510.
Medical Research Council (MRC). A trial of chemotherapy in patients with osteosarcoma (a report to the Medical Research Council by their Working Party on Bone Sarcoma). Br J Cancer.. 1986;53:513-518.
Burgers JMV, Van Glabbeke M, Busson A, et al. Osteosarcoma of the limbs: report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation. Cancer.. 1988;5:1024-1031.
Link MP, Gorrin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. New Engl J Med.. 1986;134:1600-1606.
Eilber F, Giuilano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomised prospective trial. J Clin Oncol.. 1987;5:21-26.
Bramwell VH, Burgers M, Sneath R, et al. A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. J Clin Oncol.. 1992;10:1579-1591.
Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet.. 1997;350:911-917.
Lewis IJ, Weeden S, Machin D, Stark D, Craft AW. Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma. European Osteosarcoma Intergroup. J Clin Oncol.. 2000;18:4028-4037.
Ornadel D, Souhami RL, Whelan J, et al. Doxorubicin and cisplatin with granulocyte colony-stimulating factor as adjuvant chemotherapy for osteosarcoma: phase II trial of the European Osteosarcoma Intergroup. J Clin Oncol.. 1994;12:1842-1848.
Lewis IJ, Nooij MA, Whelan J, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomised Phase III trial of the European Osteosarcoma Intergroup. JNCI. 2007;99:112-128.
Acknowledgements
The continuing support of all EOI colleagues is acknowledged along with the generous support of funding bodies to the individual groups.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Craft, A.W. (2009). Osteosarcoma: The European Osteosarcoma Intergroup (EOI) Perspective. In: Jaffe, N., Bruland, O., Bielack, S. (eds) Pediatric and Adolescent Osteosarcoma. Cancer Treatment and Research, vol 152. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0284-9_13
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0284-9_13
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-0283-2
Online ISBN: 978-1-4419-0284-9
eBook Packages: MedicineMedicine (R0)